Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 14/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 11/20 | 0.35 |
| ▸ | RARB | P10826 | 10/20 | 0.35 |
| ▸ | RARG | P13631 | 9/20 | 0.35 |
| ▸ | RXRG | P48443 | 8/20 | 0.35 |
| ▸ | RARA | P10276 | 7/20 | 0.33 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.33 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL330266 | 0.77 | RXRA (0.35) | RXRARXRBRARBRARGRXRG | |
| SCHEMBL15347776 | 0.72 | RXRA (0.50) | RXRATP53CYP1A2RXRBRARB | |
| SCHEMBL5486085 | 0.72 | RXRA (0.31) | RXRARXRBRARBRARGRXRG | |
| SCHEMBL4446990 | 0.72 | RXRA (0.36) | RXRATP53CYP1A2RXRBRARB | |
| SCHEMBL5491284 | 0.72 | RXRA (0.35) | RXRARXRBRARBRARGRXRG | |
| SCHEMBL11599145 | 0.71 | RXRA (0.42) | RXRATP53CYP1A2RXRBRARB | |
| SCHEMBL5492492 | 0.71 | RXRA (0.33) | RXRARARBRARGRARA | |
| SCHEMBL7583942 | 0.66 | RARG (0.32) | RXRARARBRARGRARACYP26A1 | |
| SCHEMBL5499418 | 0.66 | RXRA (0.39) | RXRARXRBRARBRARGRXRG | |
| SCHEMBL18327675 | 0.65 | RXRA (0.45) | RXRATP53CYP1A2RXRBRARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765719-B2 | Therapeutic drug for adult T-cell leukemia | KAGOSHIMA UNIVERSITY (JP) | 2014-07-01 | — | — | US | disclosed |
| EP-2345409-A1 | THERAPEUTIC AGENT FOR ADULT T-CELL LEUKEMIA | Kagoshima University (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-20110172185-A1 | THERAPEUTIC DRUG FOR ADULT T-CELL LEUKEMIA | KAGOSHIMA UNIVERSITY (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-1587779-A1 | 5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL 2,6-DIFLUOROHEPTATRIENOIC ACID DERIVATIVES HAVING SERUM GLUCOSE REDUCING ACTIVITY | Allergan, Inc. (US) | 2005-10-26 | — | — | EP | disclosed |
| WO-2004065345-A1 | 5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL 2,6-DIFLUOROHEPTATRIENOIC ACID DERIVATIVES HAVING SERUM GLUCOSE REDUCING ACTIVITY | ALLERGAN, INC. (US) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172185-A1 | THERAPEUTIC DRUG FOR ADULT T-CELL LEUKEMIA | CBR3, CD47, ATL3 | RXRA 1135/4885TP53 1555/4885CYP1A2 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.